Pushing the boundaries of pharmaceutical science to discover breakthrough therapies
Focused on the most pressing healthcare challenges
Developing targeted cancer therapies including immunotherapies, antibody-drug conjugates, and small molecule inhibitors for solid tumors and hematologic malignancies.
Advancing treatments for Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurodegenerative conditions through novel therapeutic approaches.
Innovating next-generation cardiovascular therapies targeting heart failure, arrhythmias, atherosclerosis, and hypertension with improved efficacy profiles.
Committed to developing orphan drugs for rare genetic disorders, leveraging gene therapy and precision medicine approaches to address unmet medical needs.
Ongoing and completed clinical studies
| Trial Name | Therapeutic Area | Phase | Status |
|---|---|---|---|
| CS-2025-01 | Cardiovascular | Phase III | Recruiting |
| NC-2024-03 | Neurology | Phase II | Active |
| IB-2025-02 | Immunology | Phase II | Recruiting |
| ONC-2024-01 | Oncology | Phase I | Active |
| RD-2025-01 | Rare Diseases | Phase I | Pending |
Our state-of-the-art Innovation Lab in New Jersey is equipped with cutting-edge technology including high-throughput screening systems, AI-powered drug discovery platforms, and advanced analytical instrumentation. This facility enables our scientists to accelerate the drug discovery process while maintaining the highest standards of quality and safety.
Collaborating with leading academic and research institutions
Oncology research collaboration
CNS drug development partnership
Cardiovascular research initiative
Peer-reviewed research from our scientific team
January 2025
March 2025
April 2025
Partner with MediSphere to advance scientific discovery and bring new therapies to patients.
Contact Our Research Team